Atai Therapeutics, Inc.
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Previously recorded as Viridia Life Sciences, Inc. (to 2023)
0
Ending by 2030
Mar 2035
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due May 28, 2027The maintenance fee for Aminotetraline Activators of Serotonin Receptors (US 11,827,580) comes due May 28, 2027. Unpaid by Nov 29, 2027, it lapses early.
- 1 fee due Sep 12, 2027The maintenance fee for Dimethoxyphenylalkylamine Activators of Serotonin Receptors (US 11,926,574) comes due Sep 12, 2027. Unpaid by Mar 13, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 20, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,561,233 | Use of ibogaine for the treatment of pain In force · From the USPTO record | In force | From the USPTO record | |
| US 9,592,239 | Methods and compositions for ibogaine treatment of impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake In force · From the USPTO record | In force | From the USPTO record | |
| US 11,077,118 | Methods and compositions for ibogaine treatment of impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake In force · From the USPTO record | In force | From the USPTO record | |
| US 10,660,900 | Methods and Compostions for Potentiating the Action of Opioid Analgesics Using Iboga Alkaloids In force · Medium confidence | In force | Medium confidence | |
| US 11,197,866 | Methods and Compositions for Potentiating the Action of Opioid Analgesics Using Iboga Alkaloids In force · Low confidence | In force | Low confidence | |
| US 11,260,059 | Methods and Compositions for Potentiating the Action of Opioid Analgesics Using Iboga Alkaloids In force · Low confidence | In force | Low confidence | |
| US 12,016,866 | Methods and Compositions for Potentiating the Action of Opioid Analgesics Using Iboga Alkaloids In force · Low confidence | In force | Low confidence | |
| US 11,478,449 | Novel Compositions of Matter and Pharmaceutical Compositions In force · High confidence | In force | High confidence | |
| US 12,053,453 | Novel Compositions of Matter and Pharmaceutical Compositions In force · High confidence | In force | High confidence | |
| US 12,396,982 | Novel Compositions of Matter and Pharmaceutical Compositions In force · High confidence | In force | High confidence |
Also on record, not counted in the 27: 1 patent in force now held by others. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
9 pending